Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib plus fulvestrant plus trastuzumab (N plus F plus T)

被引：0
|
作者：
Ma, Cynthia
Waisman, James
Brufsky, Adam M.
Yang, Eddy S.
Wildiers, Hans
Crown, John P.
Piha-Paul, Sarina A.
Suga, Jennifer M.
Garcia-Saenz, Jose Angel
Gambardella, Valentina
Guerrero, Angel
Stemmer, Salomon
Bose, Ron
Novara-Demgen, Tonya
DiPrimeo, Daniel
Eli, Lisa D.
Jhaveri, Komal
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD17-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD17-01
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Neratinib plus fulvestrant plus trastzuzumab (N plus F plus T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.
    Jhaveri, Komal L.
    Goldman, Jonathan W.
    Hurvitz, Sara A.
    Guerrero-Zotano, Angel
    Unni, Nisha
    Brufsky, Adam
    Park, Haeseong
    Waisman, James Ross
    Yang, Eddy Shih-Hsin
    Spanggaard, Iben
    Reid, Sonya A.
    Burkard, Mark E.
    Prat, Aleix
    Loi, Sherene
    Crown, John
    Hanker, Ariella
    Ma, Cynthia X.
    Bose, Ron
    Eli, Lisa DeFazio
    Wildiers, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Neratinib plus fulvestrant plus trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
    Jhaveri, K.
    Eli, L. D.
    Wildiers, H.
    Hurvitz, S. A.
    Guerrero-Zotano, A.
    Unni, N.
    Brufsky, A.
    Park, H.
    Waisman, J.
    Yang, E. S.
    Spanggaard, I.
    Reid, S.
    Burkard, M. E.
    Vinayak, S.
    Prat, A.
    Arnedos, M.
    Bidard, F. -C.
    Loi, S.
    Crown, J.
    Bhave, M.
    Piha-Paul, S. A.
    Suga, J. M.
    Chia, S.
    Saura, C.
    Garcia-Saenz, J. a.
    Gambardella, V.
    de Miguel, M. J.
    Gal-Yam, E. N.
    Raphael, A.
    Stemmer, S. M.
    Ma, C.
    Hanker, A. B.
    Ye, D.
    Goldman, J. W.
    Bose, R.
    Peterson, L.
    Bell, J. S. K.
    Frazier, A.
    Diprimeo, D.
    Wong, A.
    Arteaga, C. L.
    Solit, D. B.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 885 - 898
  • [3] Neratinib plus fulvestrant plus trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib plus trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial
    Jhaveri, Komal
    Park, Haeseong
    Waisman, James
    Goldman, Jonathan W.
    Guerrero-Zotano, Angel
    Boni, Valentina
    Haley, Barbara
    Mayer, Ingrid A.
    Brufsky, Adam
    Yang, Eddy S.
    Garcia-Saenz, Jose A.
    Bidard, Francois-Clement
    Crown, John
    Zhang, Bo
    Frazier, Aimee
    Diala, Irmina
    Eli, Lisa D.
    Barnett, Brian
    Wildiers, Hans
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Update on the phase II SUMMIT trial: Neratinib plus fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
    Smyth, L. M.
    Saura, C.
    Piha-Paul, S. A.
    Lu, J.
    Mayer, I. A.
    Brufksy, A. M.
    Spanggaard, I.
    Arnedos, M.
    Cutler, R. E.
    Hyman, D. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 10 - 11
  • [5] Neratinib plus trastuzumab plus fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT 'basket' trial
    Wildiers, Hans
    Boni, Valentina
    Saura, Cristina
    Oliveira, Mafalda
    Jhaveri, Komal
    Won, Helen
    Bidard, Francois-Clement
    Brufsky, Adam M.
    Burkard, Mark E.
    Cervantes, Andres
    Fernandez-Martos, Carlos
    Haley, Barbara
    Loi, Sherene
    Spanggaard, Iben
    Panni, Stefano
    Lu, Janice
    Dujka, Melanie E.
    Xu, Feng
    Macia, Sonia
    Eli, Lisa D.
    Lalani, Alshad S.
    Piha-Paul, Sarina
    Meric-Bernstam, Funda
    Solit, David B.
    Hyman, David M.
    CANCER RESEARCH, 2020, 80 (04)
  • [6] Latest findings from the breast cancer cohort in SUMMIT - a phase 2 'basket' trial of neratinib plus trastuzumab plus fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer
    Jhaveri, Komal
    Saura, Cristina
    Guerrero-Zotano, Angel
    Spanggaard, Iben
    Bidard, Francois-Clement
    Goldman, Jonathan W.
    Garcia-Saenz, Jose A.
    Cervantes, Andres
    Boni, Valentina
    Crown, John
    Brufsky, Adam
    Loi, Sherene
    Haley, Barbara
    Mayer, Ingrid A.
    Chia, Stephen
    Lu, Janice
    Waisman, James
    Ben-Baruch, Noa Efrat
    Burkard, Mark E.
    Suga, Jennifer M.
    Gonzalez-Cortijo, Lucia
    Perrucci, Bruno
    Xu, Feng
    Wong, Sofia
    Zhang, Jie
    Eli, Lisa D.
    Lalani, Alshad S.
    Wildiers, Hans
    CANCER RESEARCH, 2021, 81 (04)
  • [7] Efficacy of palbociclib plus fulvestrant (P plus F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA).
    Turner, Nicholas C.
    Jiang, Yuqiu
    O'Leary, Ben
    Hrebien, Sarah
    Cristofanilli, Massimo
    Andre, Fabrice
    Loibl, Sibylle
    English, Patricia A.
    Zhang, Ke
    Randolph, Sophia
    Bartlett, Cynthia Huang
    Koehler, Maria
    Loi, Sherene
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+Metastatic Breast Cancer Patients
    Tolaney, Sara M.
    Goel, Shom
    Nadal, Jorge
    Denys, Hannelore
    Borrego, Manuel R.
    Litchfield, Lacey M.
    Liu, Jiangang
    Appiah, Adams K.
    Chen, Yanyun
    Andre, Fabrice
    CLINICAL CANCER RESEARCH, 2024, 30 (01) : 39 - 49
  • [9] Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis
    Chen, Dongshao
    Xu, Fei
    Lu, Yongkui
    Xia, Wen
    Du, Caiwen
    Xiong, Dun
    Song, Dong
    Shi, Yanxia
    Yuan, Zhongyu
    Zheng, Qiufan
    Jiang, Kuikui
    An, Xin
    Xue, Cong
    Huang, Jiajia
    Bi, Xiwen
    Chen, Meiting
    Zhang, Jingmin
    Wang, Shusen
    Hong, Ruoxi
    NPJ BREAST CANCER, 2024, 10 (01)
  • [10] Primary results from a phase 2a study of zanidatamab (zani) plus palbociclib (palbo) plus fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)
    Escriva-de-Romani, Santiago
    Cejalvo, Juan Miguel
    Alba, Emilio
    Friedmann, Jennifer
    Lescure, Alvaro Rodriguez
    Savard, Marie-France
    Pezo, Rossanna C.
    Gion, Maria
    -Borrego, Manuel Ruiz
    Hamilton, Erika
    Pluard, Timothy
    Webster, Marc
    Beeram, Muralidhar
    Linden, Hannah
    Saura, Cristina
    Shpektor, Diana
    Salim, Bob
    Harvey, Phoebe
    Hurvitz, Sara
    CANCER RESEARCH, 2024, 84 (09)
12345